MeiraGTx Holdings PLC
MGTX8.470USD
+0.060+0.71%
Handelsschluss 11/07, 16:00（ET）Kurse um 15 Minuten verzögert
681.38MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über MeiraGTx Holdings PLC Unternehmen
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
MeiraGTx Holdings PLC Informationen
BörsenkürzelMGTX
Name des UnternehmensMeiraGTx Holdings PLC
IPO-datumJun 08, 2018
CEODr. Alexandria Forbes, Ph.D.
Anzahl der mitarbeiter381
WertpapierartOrdinary Share
GeschäftsjahresendeJun 08
Addresse450 East 29Th Street
StadtNEW YORK
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl10016
Telefon16468607985
Websitehttps://meiragtx.com/
BörsenkürzelMGTX
IPO-datumJun 08, 2018
CEODr. Alexandria Forbes, Ph.D.
Führungskräfte von MeiraGTx Holdings PLC
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.31M
-3.49%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
919.65K
-2.54%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
--
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+150.00%
Mr. Robert J. Wollin, J.D.
Mr. Robert J. Wollin, J.D.
General Counsel, Secretary
General Counsel, Secretary
31.15K
+50.01%
Ms. Ellen Hukkelhoven, Ph.D.
Ms. Ellen Hukkelhoven, Ph.D.
Independent Director
Independent Director
--
--
Ms. Nicole Seligman
Ms. Nicole Seligman
Independent Director
Independent Director
--
--
Mr. Neil F. J. (Lord) Mendoza
Mr. Neil F. J. (Lord) Mendoza
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.31M
-3.49%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
919.65K
-2.54%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
--
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+150.00%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Thu, Oct 2
Aktualisiert: Thu, Oct 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Perceptive Advisors LLC
15.69%
Sanofi SA
15.16%
Johnson & Johnson Innovation-JJDC, Inc.
8.26%
Adage Capital Management, L.P.
7.50%
Prosight Capital
5.70%
Andere
47.68%
Aktionäre
Aktionäre
Anteil
Perceptive Advisors LLC
15.69%
Sanofi SA
15.16%
Johnson & Johnson Innovation-JJDC, Inc.
8.26%
Adage Capital Management, L.P.
7.50%
Prosight Capital
5.70%
Andere
47.68%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
27.60%
Corporation
16.03%
Private Equity
15.69%
Venture Capital
8.26%
Investment Advisor
6.72%
Investment Advisor/Hedge Fund
5.41%
Individual Investor
4.18%
Research Firm
1.26%
Pension Fund
0.06%
Andere
14.79%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
228
52.30M
65.02%
+2.51M
2025Q2
231
67.71M
84.26%
+4.10M
2025Q1
245
80.15M
99.86%
+3.86M
2024Q4
246
77.41M
99.87%
+22.10M
2024Q3
250
64.74M
84.14%
+9.72M
2024Q2
251
52.33M
80.03%
+4.22M
2024Q1
254
51.24M
78.85%
+2.58M
2023Q4
253
50.76M
80.27%
+3.66M
2023Q3
255
41.86M
71.40%
-5.70M
2023Q2
256
41.99M
71.79%
-2.93M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Perceptive Advisors LLC
12.63M
15.69%
+45.00K
+0.36%
Jun 30, 2025
Sanofi SA
12.20M
15.16%
--
--
Jun 30, 2025
Johnson & Johnson Innovation-JJDC, Inc.
6.64M
8.26%
--
--
Jun 30, 2025
Adage Capital Management, L.P.
6.03M
7.5%
+400.00K
+7.10%
Jun 30, 2025
Prosight Capital
4.59M
5.7%
+895.88K
+24.27%
Jun 30, 2025
Rubric Capital Management LP
3.73M
4.63%
+1.95M
+109.78%
Jun 30, 2025
683 Capital Management LLC
2.69M
3.34%
+115.00K
+4.47%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.48M
3.09%
-243.04K
-8.91%
Jun 30, 2025
J. Goldman & Co., L.P.
2.04M
2.54%
+885.81K
+76.44%
Jun 30, 2025
Forbes (Alexandria)
1.36M
1.69%
-47.50K
-3.37%
Jul 08, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
iShares Micro-Cap ETF
0.06%
Goldman Sachs Innovate Equity ETF
0.05%
Vanguard US Momentum Factor ETF
0.04%
iShares Biotechnology ETF
0.04%
iShares Russell 2000 Growth ETF
0.02%
SPDR S&P International Small Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Mehr Anzeigen
ProShares Ultra Nasdaq Biotechnology
Anteil0.07%
Invesco Nasdaq Biotechnology ETF
Anteil0.07%
iShares Micro-Cap ETF
Anteil0.06%
Goldman Sachs Innovate Equity ETF
Anteil0.05%
Vanguard US Momentum Factor ETF
Anteil0.04%
iShares Biotechnology ETF
Anteil0.04%
iShares Russell 2000 Growth ETF
Anteil0.02%
SPDR S&P International Small Cap ETF
Anteil0.02%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.01%
iShares Russell 2000 Value ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
